Skip to main content
Triangle logo TriangleGet started

CUE-101 (NCT04852328)

Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma: a one-minute explainerNCT048523281 min

CUE-101 trial for Oropharyngeal Squamous Cell Carcinoma (NCT04852328). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with untreated, HPV16-positive, p16-positive oropharyngeal squamous cancer and HLA-A*0201. Stages I–III qualify except T1N0 and T2N0; upper-neck cancers of suspected oropharyngeal origin also qualify.

The idea: CUE-101 aims to expand T cells that recognize HPV16's E7 protein. Three schedules give one or two infusions within two weeks before standard treatment. Patients then receive surgery with postoperative treatment, or chemoradiation. Blood and tumor samples assess immune changes and safety.

This phase 2 study plans 30 patients. Jesse Zaretsky leads at Washington University, St. Louis, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.